Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Trial Profile

Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 22 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
    • 06 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top